Literature DB >> 23413110

17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.

Mary Hines1, Katherine A Lyseng-Williamson, Emma D Deeks.   

Abstract

Intramuscular 17 α-hydroxyprogesterone caproate (Makena(®)), a synthetic progestin, is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of a singleton spontaneous preterm birth. Makena(®) reduces the risk of preterm birth in this patient population, and is associated with improvements in certain fetal/neonatal outcomes. The use of this US FDA-approved formulation of 17 α-hydroxyprogesterone caproate reduces the inherent risks associated with the use of pharmacy-compounded formulations of the drug.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23413110     DOI： 10.1007/s40261-013-0060-6

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


  10 in total

1.  Progesterone and preterm birth prevention: translating clinical trials data into clinical practice.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2012-05       Impact factor: 8.661

2.  Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.

Authors:  Catherine Y Spong; Paul J Meis; Elizabeth A Thom; Baha Sibai; Mitchell P Dombrowski; Atef H Moawad; John C Hauth; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Menachem Miodovnik; Kenneth J Leveno; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

3.  Does progesterone treatment influence risk factors for recurrent preterm delivery?

Authors:  Paul J Meis; Mark Klebanoff; Mitchell P Dombrowski; Baha M Sibai; Sharon Leindecker; Atef H Moawad; Allison Northen; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Menachem Miodovnik; Kenneth J Leveno; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  Obstet Gynecol       Date:  2005-09       Impact factor: 7.661

Review 4.  17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.

Authors:  Emma D Deeks
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

5.  Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).

Authors:  Arnold W Cohen; Joshua A Copel; George A Macones; M Kathryn Menard; Laura Riley; George R Saade
Journal:  Obstet Gynecol       Date:  2011-06       Impact factor: 7.661

6.  Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.

Authors:  Andrei Rebarber; Niki B Istwan; Karen Russo-Stieglitz; Jane Cleary-Goldman; Debbie J Rhea; Gary J Stanziano; Daniel H Saltzman
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

7.  Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.

Authors:  Allison T Northen; Gwendolyn S Norman; Kristine Anderson; Lisa Moseley; Michelle Divito; Margaret Cotroneo; Melissa Swain; Sabine Bousleiman; Francee Johnson; Karen Dorman; Cynthia Milluzzi; Jo-Ann Tillinghast; Marcia Kerr; Gail Mallett; Elizabeth Thom; Susan Pagliaro; Garland D Anderson
Journal:  Obstet Gynecol       Date:  2007-10       Impact factor: 7.661

8.  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Authors:  Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

9.  Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.

Authors:  John L Chollet; Michael J Jozwiakowski
Journal:  Drug Dev Ind Pharm       Date:  2012-02-13       Impact factor: 3.225

10.  Pharmacy compounding primer for physicians: prescriber beware.

Authors:  Sarah Sellers; Wulf H Utian
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546
  10 in total
  1 in total

Review 1.  Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors:  Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-05       Impact factor: 12.944
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.